radiopharmaceutical therapies

Oncology

The maximum dose of radiation prescribed by the FDA may be too conservative for novel therapies. But there's no easy solution to finding a new limit.

Oncology

The pharma industry is always on the lookout for new therapeutic angles that might prove to be a competitive advantage.

News

A week after getting FDA approval for frontline breast cancer treatment, AstraZeneca's Etcamah missed the mark in a trial aiming to expand its label.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.